Comparing newer and standard immunochemotherapy for relapsed high-grade B-cell lymphoma
Compares newer and standard immune treatments in adults with returned aggressive B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Immunotherapy in Lymphoma
Key facts
- Where
- Seoul, South KoreaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 74 years old?
Source: NCT06796517, who can take part
Where in South Korea
- Seoul St. Mary HospitalSeoul, South KoreaTaking people
- Yeoido St. Mary HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sung-Soo Park
- Trial code
- NCT06796517
- Record updated
- 28 January 2025
- Original description
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:Read full original descriptionShow less
Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:
Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies?
Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes.
Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
Inclusion: Adults aged 19 to 74 years; Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma; Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma.
Exclusion: Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.); Patients who have progressed to acute leukemia; Patients who developed solid tumor during treatment.